Hara Episkopou

Cancer is a critical public health concern and the world’s leading cause of death, with annual rates significantly increasing. The most common cancer treatments are surgery, chemotherapy, radiation, and immunotherapy, but they cause adverse effects, drug resistance, and long-term consequences.
Based on the knowledge of its 3-dimensional tissue-engineered platform (derived from adipose stem cells) for local tissue healing in the regenerative medicine field, Novadip demonstrated the key role of the extracellular matrix to improve the capacity of adipose stem cells to secrete highly specific growth factors and miRNA involved in the control of the cellular proliferation and differentiation.
Although this approach was firstly applied in the field of regenerative medicine for bone reconstruction with an autologous tissue-engineered product (for large defect reconstruction to avoid amputation), and an allogenic cell-derived matrix (to improve the capacity of bone healing in a large population of patients with co-morbidities), strong scientific evidence showed that the 3-dimensional platform could propose a new alternative in the oncology field.
In this context, the aim of SOLIT project is the development of a flexible technology “Matrisome” platform to generate unique, allogeneic, and “ready to use” therapeutics which will target solid tumours through the local delivery of highly specific biomolecules with tumour suppressive properties. This project will consolidate the business models of the CER and Novadip through the development of (i) a complete platform of preclinical testing and (ii) a commercial, large-scale adipose stem cell manufacturing for allogenic cell-derived Matrisome products as a new therapeutic class of anti-cancer drugs for the IT delivery.
Connect with us